Piramal Enterprises Limited

Piramal Healthcare Limited

Piramal Life Sciences Limited

Priamal Enterprises Limited

Sivaramakrishnan Hariharan

Rosalind Adaikalasamy Marita

Swapnil Ramesh Bajare

Nabajyoti Deka

Rajiv Sharma

Sanjay Kumar

Girish Badrinath Mahajan

Nilesh Dagia

Pramod Bhaskar Kumar

Abhay Atmaram Upare

Mandar Bhonde

Owen Chambers

Aravindan Vasudevan

Damodharan Satagopan

Geetanjali Chandrashekhar Chimote

Pallavi Hanmantrao Mane

Kamlesh Jyotindra Padiya

Rhushikesh Arun Kulkarni

Taj Usman Khan

Ganesh Wagh

Mita Roy

Milind Choukekar

The present invention relates to compounds of formula (I), wherein R, R, R, R, Rand Rare as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases mediated by phosphatidylinositol-3-kinase (PI3K), mammalian target of rapamycin (mTOR), Signal transducer and activator of transcription 3 (STAT 3), tumor necrosis factor-&#x3b1; (TNF-&#x3b1;), interleukin-6 (IL-6) or a combination thereof particularly in the treatment of cancer and inflammation.

Imidazopyridine derivatives

The present invention relates to a biodegradable, inhalable microparticle formulation comprising a compound of formula I obtained by fermentation of a microorganism of thespecies (PM0626271/MTCC5447), as described in PCT application publication WO2011027290, and a biodegradable lipid for drug delivery wherein the ratio of drug (compound of formula I) to lipid is 1:15 to 1:25. The present invention also relates to the process for preparation of the formulation and to the method of treatment of pulmonary tuberculosis, multi drug resistant tuberculosis (MDRTB), methicillin resistant(MRSA) pneumonias and methicillin sensitive(MSSA) pneumonias by administering therapeutically effective amount of the formulation to a mammal in need thereof. The present invention further relates to a method of delivering the microparticle formulation to a mammal in need thereof, wherein the formulation is administered by inhalation or intratracheal instillation for pulmonary delivery.

Microparticle formulation for pulmonary drug delivery of anti infective molecule for treatment of infectious diseases

The present invention provides a continuous process for the production of 1,2,2,2-tetrafluoroethyl difluoromethyl ether (desflurane) which comprises feeding continuously optimum molar quantities of 1-chloro-2,2,2-trifluoroethyl difluoromethyl ether (CFCHClOCHF, Isoflurane) and anhydrous hydrogen fluoride, in a reactor in the vapor phase over a fluorination catalyst system comprising a metal pentahalide absorbed on a supporting substrate at a temperature ranging from 100&#xb0; C. to 180&#xb0; C., and separating 1,2,2,2-tetrafluoroethyl difluoromethyl ether (desflurane) continuously from the reactor. The process of the present invention enables continuous removal of desflurane product thereby minimizing co-production of byproducts and resulting in high conversion efficiency and yield of desflurane.

Process for production of 1,2,2,2-tetrafluoroethyl difluoromethyl ether (desflurane)

The present invention provides novel compounds represented by the general formula (I): their stereoisomers, pharmaceutically acceptable salts and their pharmaceutically acceptable solvates thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia. The invention also relates to a process for the manufacture of compounds of formula (I) and pharmaceutical compositions containing them.

Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia

The present invention provides novel compounds represented by the general formula (I): their pharmaceutically acceptable salts and their pharmaceutically acceptable solvates thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia. The invention also relates to a process for the manufacture of compounds of formula (I) and pharmaceutical compositions containing them.

3-amino-pyridine derivatives for the treatment of metabolic disorders

Growing community of inventors

Mumbai, India

Sivaramakrishnan Hariharan